Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144.46 | 145.50 | 139.41 | 131.11 | 161.19 | 133.45 | 172.00 | 163.18 | 160.06 | 162.45 | 164.58 | 165.58 |
| Expenses | 127.12 | 124.35 | 121.25 | 120.13 | 141.18 | 119.50 | 142.37 | 138.74 | 134.28 | 135.77 | 134.74 | 149.35 |
| Operating Profit | 17.34 | 21.15 | 18.16 | 10.98 | 20.01 | 13.95 | 29.63 | 24.44 | 25.78 | 26.68 | 29.84 | 16.23 |
| OPM % | 12.00% | 14.54% | 13.03% | 8.37% | 12.41% | 10.45% | 17.23% | 14.98% | 16.11% | 16.42% | 18.13% | 9.80% |
| Other Income | 0.76 | 0.69 | 0.93 | 0.94 | 1.63 | 0.84 | 1.84 | 0.35 | 0.20 | 0.18 | -3.39 | 0.36 |
| Interest | 7.67 | 8.26 | 7.46 | 7.59 | 10.15 | 10.17 | 9.04 | 7.54 | 7.12 | 7.26 | 8.06 | 7.97 |
| Depreciation | 3.24 | 3.32 | 3.28 | 3.29 | 3.32 | 3.32 | 3.37 | 3.64 | 3.70 | 3.74 | 3.23 | 4.04 |
| Profit before tax | 7.19 | 10.26 | 8.35 | 1.04 | 8.17 | 1.30 | 19.06 | 13.61 | 15.16 | 15.86 | 15.16 | 4.58 |
| Tax % | -2.50% | -0.19% | 3.23% | 0.00% | 1.84% | 5.38% | -6.30% | 0.88% | -0.13% | 0.69% | -43.14% | 29.26% |
| Net Profit | 7.36 | 10.27 | 8.08 | 1.04 | 8.02 | 1.22 | 20.26 | 13.49 | 15.18 | 15.76 | 21.70 | 3.24 |
| EPS in Rs | 2.25 | 3.14 | 2.47 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 | 4.35 | 4.52 | 6.21 | 0.93 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 500 | 578 | 600 | 650 | 653 |
| Expenses | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 476 | 506 | 523 | 544 | 554 |
| Operating Profit | 34 | 19 | -68 | 16 | 23 | 18 | 36 | 23 | 72 | 77 | 107 | 99 |
| OPM % | 8% | 4.3% | -18% | 4.1% | 6% | 4.7% | 7% | 4.7% | 12% | 13% | 16% | 15% |
| Other Income | 0 | 90 | 76 | 9 | 84 | 2 | 77 | 0 | 1 | 3 | -3 | -3 |
| Interest | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 30 | 30 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 | 15 |
| Profit before tax | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 31 | 30 | 60 | 51 |
| Tax % | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | -11% | |
| Net Profit | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 30 | 31 | 66 | 56 |
| EPS in Rs | -3.52 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 9.28 | 9.32 | 18.93 | 16.01 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | 11% | 9% | 4% | ||
| Compounded Profit Growth | 30% | 48% | 107% | 38% | ||
| Stock Price CAGR | 17% | 22% | 46% | -13% | ||
| Return on Equity | % | % | 82% | 68% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 | 35 |
| Reserves | -188 | -183 | -151 | -183 | -207 | -143 | -156 | -30 | -40 | -5 | 26 | 110 |
| Borrowings | 381 | 373 | 273 | 224 | 233 | 164 | 166 | 74 | 68 | 116 | 179 | 226 |
| Other Liabilities | 182 | 176 | 265 | 207 | 235 | 231 | 253 | 275 | 241 | 199 | 176 | 147 |
| Total Liabilities | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 518 |
| Fixed Assets | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | 229 |
| CWIP | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 | 25 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 212 | 192 | 215 | 83 | 103 | 99 | 109 | 182 | 133 | 173 | 208 | 263 |
| Total Assets | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 | 518 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 5 | 26 | 32 |
| Cash from Investing Activity | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 | -56 |
| Cash from Financing Activity | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 14 | 26 | 22 |
| Net Cash Flow | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 | -2 |
| Free Cash Flow | 35 | 22 | 29 | 30 | 25 | 36 | 12 | 42 | 7 | -9 | -22 | -28 |
| CFO/OP | 187% | 129% | 234% | -49% | 188% | 188% | 97% | 113% | 86% | 7% | 35% | 30% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 50 | 56 | 70 | 80 |
| Inventory Days | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 | 67 |
| Days Payable | 300 | 171 | 259 | 173 | 208 | 252 | 220 | 218 | 178 | 196 | 172 | 142 |
| Cash Conversion Cycle | -54 | -37 | -124 | -117 | -131 | -176 | -147 | -112 | -101 | -96 | -55 | 6 |
| Working Capital Days | -139 | -123 | -164 | -251 | -230 | -211 | -227 | -134 | -129 | -37 | 3 | 17 |
| ROCE % | 12% | 55% | -1% | 26% | 31% | 23% | 46% | 17% | 58% | 34% | 31% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 39.80% | 39.79% | 39.79% | 39.79% | 39.77% | 39.76% | 39.76% | 39.63% | 43.09% | 43.08% | 43.01% | 43.01% |
| FIIs | 0.00% | 0.00% | 0.18% | 0.22% | 1.02% | 0.84% | 1.55% | 1.59% | 0.82% | 0.72% | 0.59% | 0.89% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% |
| Public | 60.19% | 60.20% | 60.02% | 59.97% | 59.21% | 59.40% | 58.68% | 58.79% | 56.08% | 56.21% | 56.39% | 56.04% |
| No. of Shareholders | 11,634 | 11,616 | 13,087 | 14,400 | 17,199 | 17,999 | 17,889 | 17,894 | 17,717 | 17,261 | 16,732 | 17,174 |
Fundamentals
Market Cap₹ 760 Cr.
Current Price₹ 217
Stock P/E12.8
Book Value₹ 41.3
ROCE30.7 %
ROE68.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)38%
Standalone figures.
Valuation
Market capRs 692 Cr
Enterprise valueRs 910 Cr
P/E (TTM)12.38x
Price to book4.79x
Price to sales1.06x
EV / EBITDA9.50x
EV / EBIT11.22x
EV / sales1.40x
Price to cash flow21.94x
Earnings yield8.08%
P/E, 3-year average17.55x
P/B, 3-year average11.82x
P/E, 5-year average14.01x
P/B, 5-year average28.95x
Profitability
Operating margin (excl. other income)16.42%
Operating margin (incl. other income)16.01%
EBITDA margin14.69%
Pre-tax margin7.78%
Net profit margin8.56%
Net margin, latest quarter1.96%
ROE64.92%
ROCE29.49%
ROA14.20%
ROE, 3-year average142.88%
ROCE, 3-year average40.96%
ROA, 3-year average10.56%
ROE, 5-year average142.58%
ROCE, 5-year average64.59%
ROA, 5-year average10.80%
ROIC (approx.)24.72%
Tax rate-10.58%
Other income / net worth-1.84%
Growth
Sales growth (latest year)8.47%
Profit growth (latest year)116.61%
Sales CAGR, 3 years9.18%
Sales CAGR, 5 years10.63%
Sales growth QoQ0.61%
Profit growth QoQ-85.07%
Sales growth YoY (latest quarter)1.47%
Profit growth YoY (latest quarter)-75.98%
Per share
EPS (TTM)Rs 15.99
EPS (latest year)Rs 18.93
EPS (latest quarter)Rs 0.93
EPS, 3-year averageRs 12.51
EPS, 5-year averageRs 11.86
Book value per shareRs 41.34
Sales per shareRs 186.80
Cash flow per shareRs 9.02
Free cash flow per shareRs -8.01
Efficiency
Asset turnover1.26x
Fixed asset turnover2.84x
Inventory turnover6.30x
Inventory days58 days
Debtor days80 days
Debtors turnover4.54x
Creditor days142 days
Cash conversion cycle6 days
Working capital days17 days
Leverage
Total debtRs 226 Cr
Cash and bankRs 8 Cr
Net debtRs 219 Cr
Debt to equity1.57x
Net debt / EBITDA2.28x
Interest coverage2.67x
Current ratio (filing 2026-03-31)1.19x
Quick ratio (filing 2026-03-31)0.93x
Trade payables (filing 2026-03-31)Rs 107 Cr
Owners' fund to total sources27.90%
Debt to assets43.73%
Cash flow
Cash from Operating Activity (latest year)Rs 32 Cr
Cash from Investing Activity (latest year)Rs -56 Cr
Cash from Financing Activity (latest year)Rs 22 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs -28 Cr
FCFE (approx.: FCF + change in debt)Rs 20 Cr
Cash from ops / profit, 5 years0.63x
Sales to cash flow20.62x
Statement figures
Net sales (TTM)Rs 653 Cr
Net sales (latest year)Rs 650 Cr
Sales (latest quarter)Rs 166 Cr
Operating profit excl. other income (latest year)Rs 107 Cr
Operating profit (latest quarter)Rs 16 Cr
Other income (TTM)Rs -3 Cr
EBITDA (TTM)Rs 96 Cr
PBDT (TTM)Rs 65 Cr
Profit before tax (TTM)Rs 51 Cr
Tax (latest year)Rs -6 Cr
Net profit (TTM)Rs 56 Cr
Net profit (latest year)Rs 66 Cr
Net profit (latest quarter)Rs 3 Cr
Depreciation (TTM)Rs 15 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 30 Cr
Cost of goods sold (latest year)Rs 319 Cr
Total expenditure (latest year)Rs 544 Cr
Total income (latest year)Rs 648 Cr
Share capitalRs 35 Cr
ReservesRs 110 Cr
Shareholders' fundsRs 144 Cr
Total assetsRs 518 Cr
Net blockRs 229 Cr
Capital work in progressRs 25 Cr
InvestmentsRs 0 Cr
ReceivablesRs 143 Cr
InventoryRs 51 Cr
Other liabilitiesRs 147 Cr
Shares outstanding (crore)3.49
Ownership
Promoter holding43.01% (+3.38 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 12.4 is at the 57th percentile of its own 5.4-year range
(median 4.5, low 1.3, high 45.1).
P/B 4.79 is the lowest in 3.4 years (median 27.05).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | WANBURY | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -12.1% | -2.8% | -9.3 pts |
| 1 month | -22.2% | -6.8% | -15.4 pts |
| 3 months | -30.9% | -7.6% | -23.3 pts |
| 6 months | -10.8% | +0.4% | -11.2 pts |
| 1 year | -21.5% | -9.9% | -11.6 pts |
| 2 years | -28.4% | -13.6% | -14.9 pts |
| 3 years | +186.7% | +14.2% | +172.6 pts |
| 5 years | +153.3% | +27.9% | +125.5 pts |
1 mutual fund schemes hold about ₹0 Cr.
Over three months 1 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | 0.03% | 0 | +24% |
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was 49% of net profit over the last 3 years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹166 Cr +1.5% vs Jun 2025.
Net profit ₹3 Cr -76.0%.
Against our estimate for Jun 2026: sales -6.7%, profit -81.0% miss. Our estimate for Sep 2026: sales Rs 158 Cr, profit Rs 15 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-09-20 | Annual General Meeting | |
| 2023-11-10 | Extra Ordinary General Meeting | |
| 2023-09-20 | Annual General Meeting | |
| 2023-08-14 | Extra-Ordinary General Meeting | |
| 2022-09-20 | Annual General Meeting | |
| 2021-09-17 | Annual General Meeting | |
| 2021-03-10 | Extra Ordinary General Meeting | |
| 2020-09-18 | Annual General Meeting | |
| 2019-09-20 | Annual General Meeting | |
| 2018-09-18 | Annual General Meeting | |
| 2017-09-21 | Annual General Meeting | |
| 2016-09-21 | Annual General Meeting | |
| 2015-09-18 | Annual General Meeting | |
| 2015-03-12 | Annual General Meeting | |
| 2013-09-26 | Annual Book Closure | |
| 2012-09-13 | Annual General Meeting | |
| 2011-09-19 | Annual General Meeting | |
| 2010-07-29 | Dividend-Rs.1/- Per Share | |
| 2009-09-17 | Annual General Meeting | |
| 2009-03-12 | Agm/Dividend - 5% | |
| 2007-09-13 | Agm/Dividend-20% |
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
| Order date | Forum | Case |
|---|---|---|
| 2017-08-11 | NCLAT | Wanbury Ltd. VS Panacea Biotech Ltd |
| 2017-07-21 | NCLAT | Wanbury Ltd. VS Panacea Biotech Ltd |
| 2017-06-02 | NCLAT | Wanbury Ltd. VS Panacea Biotech Ltd |
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
High low price variation greater than 75perc in previous 3 months
Quick answers
What is the market cap of Wanbury Ltd?
Wanbury Ltd (WANBURY) has a market capitalisation of Rs 760 Cr. at the 2026-10-01 close.
What is the P/E ratio of Wanbury Ltd?
Wanbury Ltd trades at a P/E of 12.8 on trailing twelve-month profit, at the 2026-10-01 close.
What were Wanbury Ltd's latest quarterly results?
In the Jun 2026 quarter, Wanbury Ltd sales was Rs 166 Cr (+1.5% vs Jun 2025) and net profit was Rs 3 Cr.
What is the 52-week high and low of Wanbury Ltd?
The 52-week high is Rs 358.85 and the 52-week low is Rs 161.50.